Literature DB >> 22287767

Mini-laparotomy versus vaginal surgery for class II-III obese patients with early-stage endometrial cancer.

Massimiliano Fambrini1, Annalisa Pieralli, Ubaldo Bitossi, Karin L Andersson, Gianfranco Scarselli, Lorenzo Livi, Gianluigi Taddei, Mauro Marchionni.   

Abstract

AIM: To compare minilaparotomic and vaginal surgery in selected obese patients with early-stage endometrial cancer at high surgical risk. PATIENTS AND METHODS: Data of 37 consecutive class II-III obese patients submitted to minilaparotomic surgery were retrospectively reviewed. Thirty-seven women matched for demographic characteristics, BMI and stage of disease submitted to vaginal surgery in the same period comprised the control group.
RESULTS: No difference was observed concerning intra- and postoperative data among the two groups. The patients who were submitted to general anesthesia exhibited a larger use of supplemental drugs for pain control (p>0.01), a higher incidence of thromboembolic events (p>0.005) and a longer hospitalization (p>0.02). No statistical difference was observed in terms of pattern of recurrence, disease-free survival and overall survival between the two groups of patients.
CONCLUSION: Obese patients with endometrial cancer unfit for vaginal surgery can be safely managed through mini-laparotomy with the same surgical and oncological outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22287767

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

Review 1.  The Impact of Obesity on Surgical Outcome in Endometrial Cancer Patients: A Systematic Review.

Authors:  Olubunmi Orekoya; Marsha E Samson; Tushar Trivedi; Shraddha Vyas; Susan E Steck
Journal:  J Gynecol Surg       Date:  2016-06-01

2.  Impact of Morbid Obesity on the Outcomes of Type II Endometrial Cancer: a Cohort Study.

Authors:  Khaled Gaballa; Islam H Metwally; Basel Refky; Shadi Awny; Mohamed Abdelkhalek; Mohamed Hamdy
Journal:  Indian J Surg Oncol       Date:  2022-01-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.